MHD technology draws micro-samples of interstitial fluid through the skin. It measures glucose with established electrochemical sensor technology. The single-day sensor system delivers a periodic, personalized monitoring alternative to standard continuous glucose monitor (CGM) devices.

Helsinki, Finland-based GlucoModicum’s method, like existing CGMs from Abbott and Dexcom, measures glucose through established glucose oxidase enzyme chemistry. However, the company aims to offer an option for people who don’t require 24/7 monitoring.